What is Fibroblast?
Fibroblast operates as a sophisticated referral management platform designed to rectify inefficiencies within the healthcare referral process. By equipping providers with intuitive, end-to-end tools, the company actively manages patient referrals. This proactive approach aims to significantly reduce patient leakage, thereby enhancing revenue streams for fee-for-service organizations. Furthermore, it mitigates risks for accountable care organizations, delivering a demonstrable return on investment through improved operational workflows and patient continuity.
How much funding has Fibroblast raised?
Fibroblast has raised a total of $2.9M across 3 funding rounds:
Private Equity
$727K
Private Equity
$2M
Debt
$150K
Private Equity (2013): $727K, investors not publicly disclosed
Private Equity (2018): $2M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in Fibroblast
PPP
Public-Private Partnership
What's next for Fibroblast?
With a significant enterprise-level funding context, Fibroblast appears poised for a scaling phase, likely focusing on expanding its market reach and enhancing its platform's capabilities. The strategic nature of its recent investment suggests a focus on deepening partnerships within the healthcare ecosystem and potentially integrating with broader health information exchange networks. Future developments may involve leveraging data analytics to further refine referral pathways and demonstrate value to a wider array of healthcare stakeholders, solidifying its position as a key player in revenue cycle management and patient engagement solutions.
See full Fibroblast company page
